Diabetes mellitus and atypical antipsychotics;Diabetes mellitus e antipsicóticos atípicos

Revista Brasileira de Psiquiatria

Volumn 25, Issue 4, 2003, Pages 253-257

  De Sena, Eduardo Pondé ^a,b   Santos Sampaio, Aline ^a   De Castro Quarantini, Lucas ^a   De Oliveira, Irismar Reis ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Antipsychotic agents; Diabetes mellitus; Hyperglycemia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; DIABETES MELLITUS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; MENTAL PATIENT; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

EID: 0242403092     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462003000400014     Document Type: Review

References (45)

1. Ratner RE. Type 2 diabetes mellitus: the grand overview. Diabet Med 1998;15(Suppl 4):S4-S7.
2. Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001;13(4):241-2.
3. Oliveira IR. Antipsicóticos atípicos: farmacologia e uso clínico. Rev Bras Psiquiatr 2000; 22(Supl I):38-40.
4. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15-26.
5. Meyer JM. Effect of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62(Suppl 27):27-34.
6. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001;62(Suppl 27):35-9.
7. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73.
8. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and empaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey. 1998-1994. Diabetes Care 1998;21:518-24.
9. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
10. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Pychiatry 2001;62(Suppl 23):30-8.
11. Komegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002;63(9):758-62.
12. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64.
13. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001;101(3):277-88.
14. Defronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Metab Rev 1997;5:177-269.
15. Arneson, G.A. Phenotiazine derivatives and glucose metabolism. J Neuropsychiatry 1964;5:181-5.
16. Kamath V, Jones CN, Yip JC, Varasteh BB, Cincota AH, Reaven GM, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997;20:1697-701.
17. Wick JY. Atypical antipsyhotics. Consultant Pharmacist 1998:1-9.
18. Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001;62(Suppl 27):5-9.
19. Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol 1977;11:15-8.
20. Wosniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991;49:101-9.
21. 2A receptors in the rat brain. Neuropsychopharm 1997;16(3):183-90.
22. Tecott LH, Sun LM, Akana SF, Strack AM, Lowestein DH, Dallman MF. et al. Eating disorder and epilepsy in mice lacking 5-TH2c serotonin receptors. Nature 1995:374:542-6.
23. Curson G, Gibson EL, Oluyumi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors, but not on 5-HT availability. Trends Pharmacol Sci 1997;18:21-5.
24. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999;130:671-80.
25. Hagg S, Joelsson L, Mjordnal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59(6):294-9.
26. Henderson DC. Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schonenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five years naturalistic study. Am J Psychiatry 2000:157(6):975-81.
27. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58(12):1172-6.
28. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated diabetes. Biol Psychiatry 2001;50(2):148-9.
29. Baker R. Comparing glicemic profiles across treatment options in psychatric disorders. Data on file, Elli Lilly and Co; 2002.
30. Wirshing DA, Erhart SM, Pierre JM, Boyd JA. Nonextrapyramidal side effects of novel antipsychotics. Curr Opin Psychiatry 2000; 13:45-50.
31. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;1(1):25-32.
32. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40(5):438-43.
33. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000;34:865-7.
34. Bonnano DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001;35:563-5.
35. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002;325:243.
36. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63(5):425-33.
37. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59(4):337-45.
38. Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance on 8858 patients in England. J Psychopharmacol 2001;15(4):265-71.
39. Sobel M, Jagers E.D, Franz MA. New onset diabetes mellitus associated with the initiation of quetiapine treatment (letter). J Clin Psychiatry 1999;60:556-7.
40. Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA. Effect of clozapine-quetiapine combination therapy on weight and glycemic control. Clin Drug Invest 1999;18:99-104.
41. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on diagnosis and classification of diabetes mellitus. Diabetes Care 2000;23:S4-S19.
42. Diet and exercise dramatically delay type 2 diabetes: diabetes medication metformin also effective (press release). Aug, 2001. Available at: http://www.niddk.nih.gov/welcome/releases/8_8_01.html.
43. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001;62(27):10-4.
44. Serniak MJ, Lesklie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159(4):561-6.
45. Geddes J, Freemantle N, Harisson P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6.